Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Avadel Pharmaceuticals ( (AVDL) ).
On January 19, 2026, Avadel Pharmaceuticals announced that the High Court of Ireland has scheduled a sanction hearing for February 10, 2026 to consider a scheme of arrangement under which Alkermes plc will acquire all issued and to-be-issued ordinary shares of Avadel. The offer period for this takeover began on October 22, 2025, and the transaction is expected to close shortly after the court sanctions the scheme, with the company outlining Irish Takeover Rules disclosure obligations for shareholders holding or dealing in 1% or more of Avadel’s relevant securities, underscoring the formal progression and regulatory framework of the pending acquisition.
The most recent analyst rating on (AVDL) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Avadel Pharmaceuticals stock, see the AVDL Stock Forecast page.
Spark’s Take on AVDL Stock
According to Spark, TipRanks’ AI Analyst, AVDL is a Neutral.
The score is driven primarily by improving operational trends (revenue growth and strong cash-flow improvement) and a stable balance sheet with minimal leverage, but held back by continued lack of profitability (negative net margin and ROE). Technicals are moderately positive, while valuation is weak due to losses and a negative P/E. Corporate events provide meaningful upside support via the approved acquisition and other favorable developments.
To see Spark’s full report on AVDL stock, click here.
More about Avadel Pharmaceuticals
Average Trading Volume: 3,099,558
Technical Sentiment Signal: Buy
Current Market Cap: $2.1B
For an in-depth examination of AVDL stock, go to TipRanks’ Overview page.